Biolocity graduate company, NephroDI Therapeutics, recently raised $1.6M to advance the development of a treatment for Nephrogenic Diabetes Insipidus (NDI), a pediatric kidney disease. The team is collaborating with Xontogeny, a Boston based life sciences accelerator, to support their creation of therapies to treat children suffering from NDI. Learn more about their collaboration here.
The NephroDI Team, Dr. Jeff Sands and Dr. Janet Klein, received support from the Biolocity program in 2018 and we are thrilled for their continued success and technology development.
“The Biolocity team provided invaluable assistance that moved our project from an NIH focus to a commercial venture. They recognized the value of our technology and how to promote it to industry. We would not have succeeded without their expertise.”
– Jeff M. Sands, MD, Renal Division Director, Emory University